These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 23110940)

  • 41. The efficacy and roles of combining temozolomide with whole brain radiotherapy in protection neurocognitive function and improvement quality of life of non-small-cell lung cancer patients with brain metastases.
    Deng X; Zheng Z; Lin B; Su H; Chen H; Fei S; Fei Z; Zhao L; Jin X; Xie CY
    BMC Cancer; 2017 Jan; 17(1):42. PubMed ID: 28068937
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The Impact of EGFR Mutation Status and Brain Metastasis for Non-Small Cell Lung Cancer Treated with Ramucirumab plus Docetaxel.
    Furuya N; Ito K; Sakaguchi T; Hida N; Kakinuma K; Morikawa K; Inoue T; Komase Y; Hataji O; Mineshita M
    Oncology; 2020; 98(9):661-668. PubMed ID: 32464632
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Epidermal growth factor receptor mutation and pattern of brain metastasis in patients with non-small cell lung cancer.
    Baek MY; Ahn HK; Park KR; Park HS; Kang SM; Park I; Kim YS; Hong J; Sym SJ; Park J; Lee JH; Shin DB; Cho EK
    Korean J Intern Med; 2018 Jan; 33(1):168-175. PubMed ID: 27093978
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Outcomes after combined modality therapy for EGFR-mutant and wild-type locally advanced NSCLC.
    Mak RH; Doran E; Muzikansky A; Kang J; Neal JW; Baldini EH; Choi NC; Willers H; Jackman DM; Sequist LV
    Oncologist; 2011; 16(6):886-95. PubMed ID: 21632451
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Targeted sequencing and intracranial outcomes of patients with lung adenocarcinoma brain metastases treated with radiotherapy.
    Press RH; Zhang C; Cassidy RJ; Ferris MJ; Zhong J; Steuer CE; Pillai RN; Owonikoko TK; Kahn S; Ramalingam SS; Patel PR; Curran WJ; Shu HG; Sica GL; Higgins KA
    Cancer; 2018 Sep; 124(17):3586-3595. PubMed ID: 30120912
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Outcome and prognostic factors in patients with brain metastases from small-cell lung cancer treated with whole brain radiotherapy.
    Bernhardt D; Adeberg S; Bozorgmehr F; Opfermann N; Hoerner-Rieber J; König L; Kappes J; Thomas M; Herth F; Heußel CP; Warth A; Debus J; Steins M; Rieken S
    J Neurooncol; 2017 Aug; 134(1):205-212. PubMed ID: 28560661
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Correlation of EGFR mutation subtypes and survival in surgically treated brain metastasis from non-small-cell lung cancer.
    Perng PS; Hsu HP; Lee PH; Huang CC; Lin CC; Lee JS
    Asian J Surg; 2023 Jan; 46(1):269-276. PubMed ID: 35393224
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prognostic factors for brain metastases from non-small cell lung cancer with EGFR mutation: influence of stable extracranial disease and erlotinib therapy.
    Sekine A; Satoh H; Iwasawa T; Tamura K; Hayashihara K; Saito T; Kato T; Arai M; Okudela K; Ohashi K; Ogura T
    Med Oncol; 2014 Oct; 31(10):228. PubMed ID: 25208818
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Icotinib is as efficacious as gefitinib for brain metastasis of EGFR mutated non-small-cell lung cancer.
    Liu K; Jiang G; Zhang A; Li Z; Jia J
    BMC Cancer; 2020 Jan; 20(1):76. PubMed ID: 32000711
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Co-occurring genetic alterations predict distant metastasis and poor efficacy of first-line EGFR-TKIs in EGFR-mutant NSCLC.
    Deng LL; Gao G; Deng HB; Wang F; Wang ZH; Yang Y
    J Cancer Res Clin Oncol; 2019 Oct; 145(10):2613-2624. PubMed ID: 31463717
    [TBL] [Abstract][Full Text] [Related]  

  • 51. EGFR Exon 19 Deletion is Associated With Favorable Overall Survival After First-line Gefitinib Therapy in Advanced Non-Small Cell Lung Cancer Patients.
    Choi YW; Jeon SY; Jeong GS; Lee HW; Jeong SH; Kang SY; Park JS; Choi JH; Koh YW; Han JH; Sheen SS
    Am J Clin Oncol; 2018 Apr; 41(4):385-390. PubMed ID: 26967328
    [TBL] [Abstract][Full Text] [Related]  

  • 52. First-line epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor alone or with whole-brain radiotherapy for brain metastases in patients with EGFR-mutated lung adenocarcinoma.
    Chen Y; Yang J; Li X; Hao D; Wu X; Yang Y; He C; Wang W; Wang J
    Cancer Sci; 2016 Dec; 107(12):1800-1805. PubMed ID: 27627582
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prognostic factors affecting survival after whole brain radiotherapy in patients with brain metastasized lung cancer.
    Tsakonas G; Hellman F; Gubanski M; Friesland S; Tendler S; Lewensohn R; Ekman S; de Petris L
    Acta Oncol; 2018 Feb; 57(2):231-238. PubMed ID: 28984492
    [TBL] [Abstract][Full Text] [Related]  

  • 54. EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer.
    Eichler AF; Kahle KT; Wang DL; Joshi VA; Willers H; Engelman JA; Lynch TJ; Sequist LV
    Neuro Oncol; 2010 Nov; 12(11):1193-9. PubMed ID: 20627894
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Stereotactic radiotherapy vs whole brain radiation therapy in EGFR mutated NSCLC: Results & reflections from the prematurely closed phase III HYBRID trial.
    Zeng M; Verma V; Chen X; Li S; Sun Y; Liu G; Tian X; Zhang D; Li J; Liu Y; Liao X; Liu Y; Wang L; Wang X; Shi H; Li B; Xue B; Luo X
    Radiother Oncol; 2024 Aug; 197():110334. PubMed ID: 38801945
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Whole brain radiotherapy plus simultaneous in-field boost with image guided intensity-modulated radiotherapy for brain metastases of non-small cell lung cancer.
    Zhou L; Liu J; Xue J; Xu Y; Gong Y; Deng L; Wang S; Zhong R; Ding Z; Lu Y
    Radiat Oncol; 2014 May; 9():117. PubMed ID: 24884773
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A review of whole brain radiotherapy outcomes in a high epidermal growth factor receptor mutation rate population: Does QUARTZ apply in Asia?
    Ng IW; Tey JCS; Chia DWT; Yee CM; Cheo TST
    Asia Pac J Clin Oncol; 2019 Dec; 15(6):353-357. PubMed ID: 31267659
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Incorporation of EGFR mutation status into M descriptor of new TNM classification influences survival curves in non-small cell lung cancer patients.
    Stanic K; Turnsek N; Vrankar M
    Radiol Oncol; 2019 Nov; 53(4):453-458. PubMed ID: 31747381
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Epidermal Growth Factor Receptor Mutation Status Confers Survival Benefit in Patients with Non-Small-Cell Lung Cancer Undergoing Surgical Resection of Brain Metastases: A Retrospective Cohort Study.
    Huang Y; Chow KKH; Aredo JV; Padda SK; Han SS; Kakusa BW; Hayden Gephart M
    World Neurosurg; 2019 May; 125():e487-e496. PubMed ID: 30710723
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Patient selection for whole brain radiotherapy (WBRT) in a large lung cancer cohort: Impact of a new Dutch guideline on brain metastases.
    Hendriks LE; Troost EG; Steward A; Bootsma GP; De Jaeger K; van den Borne BE; Dingemans AM
    Acta Oncol; 2014 Jul; 53(7):945-51. PubMed ID: 24754845
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.